Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder

Heather A. Berlin, Lorrin M. Koran, Michael A. Jenike, Nathan A. Shapira, William Chaplin, Stefano Pallanti, Eric Hollander

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background: From 40% to 60% of obsessive-compulsive disorder (OCD) patients fail to tolerate or respond to selective serotonin reuptake inhibitors (SSRIs). Preclinical and neuroimaging studies have shown abnormally high glutamatergic concentrations in OCD patients and an association between decreased caudate glutamatergic concentrations and reduced OCD symptom severity after SSRI treatment. Topiramate inhibits glutamatergic conduction. Method: Thirty-six adult patients with DSM-IV-defined OCD were randomly assigned to topiramate (n = 18) and placebo (n = 18) groups in this 12-week, double-blind, placebo-controlled, parallel-groups trial. Subjects were taking the maximum SSRI dose they could tolerate for at least 12 weeks and their current dose for at least 6 weeks, which was maintained throughout the study. Primary outcome measures were changes in the Yale-Brown Obsessive Compulsive Scale (YBOCS) total score and compulsions and obsessions subscores. Patients were recruited and followed up between April 1, 2003, and April 13, 2006. Results: Using mixed regression models (time [weeks] x treatment), we found a significant treatment effect on the YBOCS compulsions (P = .014) subscale, but not the obsessions (P = .99) subscale or the total score (P = .11). Over the 12-week trial, the topiramate group (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d) showed an average linear decrease of 5.38 points on the compulsions subscale compared to 0.6 points in the placebo group. Thirteen topiramate and 14 placebo subjects completed the study. Topiramate was not well tolerated in this trial: 28% (5/18) of the subjects discontinued the drug for adverse effects, and 39% (7/18) had a dose reduction for this reason. Conclusions: The results of this first double-blind, placebo-controlled trial of topiramate augmentation for treatment-resistant OCD suggest that topiramate may be beneficial for compulsions, but not obsessions. Modifications in glutamatergic function may be responsible, at least in part, for the improved response in compulsions seen with topiramate. Trial Registration: clinicaltrials.gov Identifier: NCT00211744.

Original languageEnglish (US)
Pages (from-to)716-721
Number of pages6
JournalJournal of Clinical Psychiatry
Volume72
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Obsessive-Compulsive Disorder
Placebos
Obsessive Behavior
Serotonin Uptake Inhibitors
Therapeutics
topiramate
Neuroimaging
Diagnostic and Statistical Manual of Mental Disorders
Outcome Assessment (Health Care)
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. / Berlin, Heather A.; Koran, Lorrin M.; Jenike, Michael A.; Shapira, Nathan A.; Chaplin, William; Pallanti, Stefano; Hollander, Eric.

In: Journal of Clinical Psychiatry, Vol. 72, No. 5, 05.2011, p. 716-721.

Research output: Contribution to journalArticle

Berlin, Heather A. ; Koran, Lorrin M. ; Jenike, Michael A. ; Shapira, Nathan A. ; Chaplin, William ; Pallanti, Stefano ; Hollander, Eric. / Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. In: Journal of Clinical Psychiatry. 2011 ; Vol. 72, No. 5. pp. 716-721.
@article{56360bfe70544543b072602c80e38e9a,
title = "Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder",
abstract = "Background: From 40{\%} to 60{\%} of obsessive-compulsive disorder (OCD) patients fail to tolerate or respond to selective serotonin reuptake inhibitors (SSRIs). Preclinical and neuroimaging studies have shown abnormally high glutamatergic concentrations in OCD patients and an association between decreased caudate glutamatergic concentrations and reduced OCD symptom severity after SSRI treatment. Topiramate inhibits glutamatergic conduction. Method: Thirty-six adult patients with DSM-IV-defined OCD were randomly assigned to topiramate (n = 18) and placebo (n = 18) groups in this 12-week, double-blind, placebo-controlled, parallel-groups trial. Subjects were taking the maximum SSRI dose they could tolerate for at least 12 weeks and their current dose for at least 6 weeks, which was maintained throughout the study. Primary outcome measures were changes in the Yale-Brown Obsessive Compulsive Scale (YBOCS) total score and compulsions and obsessions subscores. Patients were recruited and followed up between April 1, 2003, and April 13, 2006. Results: Using mixed regression models (time [weeks] x treatment), we found a significant treatment effect on the YBOCS compulsions (P = .014) subscale, but not the obsessions (P = .99) subscale or the total score (P = .11). Over the 12-week trial, the topiramate group (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d) showed an average linear decrease of 5.38 points on the compulsions subscale compared to 0.6 points in the placebo group. Thirteen topiramate and 14 placebo subjects completed the study. Topiramate was not well tolerated in this trial: 28{\%} (5/18) of the subjects discontinued the drug for adverse effects, and 39{\%} (7/18) had a dose reduction for this reason. Conclusions: The results of this first double-blind, placebo-controlled trial of topiramate augmentation for treatment-resistant OCD suggest that topiramate may be beneficial for compulsions, but not obsessions. Modifications in glutamatergic function may be responsible, at least in part, for the improved response in compulsions seen with topiramate. Trial Registration: clinicaltrials.gov Identifier: NCT00211744.",
author = "Berlin, {Heather A.} and Koran, {Lorrin M.} and Jenike, {Michael A.} and Shapira, {Nathan A.} and William Chaplin and Stefano Pallanti and Eric Hollander",
year = "2011",
month = "5",
doi = "10.4088/JCP.09m05266gre",
language = "English (US)",
volume = "72",
pages = "716--721",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5",

}

TY - JOUR

T1 - Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder

AU - Berlin, Heather A.

AU - Koran, Lorrin M.

AU - Jenike, Michael A.

AU - Shapira, Nathan A.

AU - Chaplin, William

AU - Pallanti, Stefano

AU - Hollander, Eric

PY - 2011/5

Y1 - 2011/5

N2 - Background: From 40% to 60% of obsessive-compulsive disorder (OCD) patients fail to tolerate or respond to selective serotonin reuptake inhibitors (SSRIs). Preclinical and neuroimaging studies have shown abnormally high glutamatergic concentrations in OCD patients and an association between decreased caudate glutamatergic concentrations and reduced OCD symptom severity after SSRI treatment. Topiramate inhibits glutamatergic conduction. Method: Thirty-six adult patients with DSM-IV-defined OCD were randomly assigned to topiramate (n = 18) and placebo (n = 18) groups in this 12-week, double-blind, placebo-controlled, parallel-groups trial. Subjects were taking the maximum SSRI dose they could tolerate for at least 12 weeks and their current dose for at least 6 weeks, which was maintained throughout the study. Primary outcome measures were changes in the Yale-Brown Obsessive Compulsive Scale (YBOCS) total score and compulsions and obsessions subscores. Patients were recruited and followed up between April 1, 2003, and April 13, 2006. Results: Using mixed regression models (time [weeks] x treatment), we found a significant treatment effect on the YBOCS compulsions (P = .014) subscale, but not the obsessions (P = .99) subscale or the total score (P = .11). Over the 12-week trial, the topiramate group (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d) showed an average linear decrease of 5.38 points on the compulsions subscale compared to 0.6 points in the placebo group. Thirteen topiramate and 14 placebo subjects completed the study. Topiramate was not well tolerated in this trial: 28% (5/18) of the subjects discontinued the drug for adverse effects, and 39% (7/18) had a dose reduction for this reason. Conclusions: The results of this first double-blind, placebo-controlled trial of topiramate augmentation for treatment-resistant OCD suggest that topiramate may be beneficial for compulsions, but not obsessions. Modifications in glutamatergic function may be responsible, at least in part, for the improved response in compulsions seen with topiramate. Trial Registration: clinicaltrials.gov Identifier: NCT00211744.

AB - Background: From 40% to 60% of obsessive-compulsive disorder (OCD) patients fail to tolerate or respond to selective serotonin reuptake inhibitors (SSRIs). Preclinical and neuroimaging studies have shown abnormally high glutamatergic concentrations in OCD patients and an association between decreased caudate glutamatergic concentrations and reduced OCD symptom severity after SSRI treatment. Topiramate inhibits glutamatergic conduction. Method: Thirty-six adult patients with DSM-IV-defined OCD were randomly assigned to topiramate (n = 18) and placebo (n = 18) groups in this 12-week, double-blind, placebo-controlled, parallel-groups trial. Subjects were taking the maximum SSRI dose they could tolerate for at least 12 weeks and their current dose for at least 6 weeks, which was maintained throughout the study. Primary outcome measures were changes in the Yale-Brown Obsessive Compulsive Scale (YBOCS) total score and compulsions and obsessions subscores. Patients were recruited and followed up between April 1, 2003, and April 13, 2006. Results: Using mixed regression models (time [weeks] x treatment), we found a significant treatment effect on the YBOCS compulsions (P = .014) subscale, but not the obsessions (P = .99) subscale or the total score (P = .11). Over the 12-week trial, the topiramate group (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d) showed an average linear decrease of 5.38 points on the compulsions subscale compared to 0.6 points in the placebo group. Thirteen topiramate and 14 placebo subjects completed the study. Topiramate was not well tolerated in this trial: 28% (5/18) of the subjects discontinued the drug for adverse effects, and 39% (7/18) had a dose reduction for this reason. Conclusions: The results of this first double-blind, placebo-controlled trial of topiramate augmentation for treatment-resistant OCD suggest that topiramate may be beneficial for compulsions, but not obsessions. Modifications in glutamatergic function may be responsible, at least in part, for the improved response in compulsions seen with topiramate. Trial Registration: clinicaltrials.gov Identifier: NCT00211744.

UR - http://www.scopus.com/inward/record.url?scp=79959251365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959251365&partnerID=8YFLogxK

U2 - 10.4088/JCP.09m05266gre

DO - 10.4088/JCP.09m05266gre

M3 - Article

VL - 72

SP - 716

EP - 721

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5

ER -